LSTA
Price
$2.41
Change
-$0.04 (-1.63%)
Updated
Oct 21, 04:59 PM (EDT)
Capitalization
21.45M
16 days until earnings call
Intraday Buy/Sell Signals
RCUS
Price
$18.05
Change
+$0.58 (+3.32%)
Updated
Oct 21, 04:59 PM (EDT)
Capitalization
1.86B
21 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

LSTA vs RCUS

Header iconLSTA vs RCUS Comparison
Open Charts LSTA vs RCUSBanner chart's image
Lisata Therapeutics
Price$2.41
Change-$0.04 (-1.63%)
Volume$315
Capitalization21.45M
Arcus Biosciences
Price$18.05
Change+$0.58 (+3.32%)
Volume$19.17K
Capitalization1.86B
LSTA vs RCUS Comparison Chart in %
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LSTA vs. RCUS commentary
Oct 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSTA is a Hold and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 22, 2025
Stock price -- (LSTA: $2.45 vs. RCUS: $17.47)
Brand notoriety: LSTA and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSTA: 87% vs. RCUS: 105%
Market capitalization -- LSTA: $21.45M vs. RCUS: $1.86B
LSTA [@Biotechnology] is valued at $21.45M. RCUS’s [@Biotechnology] market capitalization is $1.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSTA’s FA Score shows that 1 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • LSTA’s FA Score: 1 green, 4 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both LSTA and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSTA’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 3 bullish TA indicator(s).

  • LSTA’s TA Score: 5 bullish, 5 bearish.
  • RCUS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, LSTA is a better buy in the short-term than RCUS.

Price Growth

LSTA (@Biotechnology) experienced а +0.82% price change this week, while RCUS (@Biotechnology) price change was +4.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.56%. For the same industry, the average monthly price growth was +22.45%, and the average quarterly price growth was +71.53%.

Reported Earning Dates

LSTA is expected to report earnings on Nov 06, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+8.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.86B) has a higher market cap than LSTA($21.5M). RCUS YTD gains are higher at: 17.327 vs. LSTA (-17.785). LSTA has higher annual earnings (EBITDA): -20.83M vs. RCUS (-282M). RCUS has more cash in the bank: 911M vs. LSTA (22M). LSTA has less debt than RCUS: LSTA (47K) vs RCUS (109M). RCUS has higher revenues than LSTA: RCUS (262M) vs LSTA (1.07M).
LSTARCUSLSTA / RCUS
Capitalization21.5M1.86B1%
EBITDA-20.83M-282M7%
Gain YTD-17.78517.327-103%
P/E RatioN/AN/A-
Revenue1.07M262M0%
Total Cash22M911M2%
Total Debt47K109M0%
FUNDAMENTALS RATINGS
LSTA vs RCUS: Fundamental Ratings
LSTA
RCUS
OUTLOOK RATING
1..100
2375
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
5537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (17) in the null industry is somewhat better than the same rating for RCUS (62) in the Pharmaceuticals Major industry. This means that LSTA’s stock grew somewhat faster than RCUS’s over the last 12 months.

LSTA's Profit vs Risk Rating (100) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that LSTA’s stock grew similarly to RCUS’s over the last 12 months.

LSTA's SMR Rating (98) in the null industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that LSTA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as LSTA (55) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

RCUS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as LSTA (100) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LSTARCUS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIXIX10.73N/A
N/A
Nationwide International Index R6
SBPYX43.41N/A
N/A
ClearBridge Small Cap Growth I
IEIFX11.17N/A
N/A
Invesco Equity and Income R6
MGOTX8.79N/A
N/A
Victory Munder Mid-Cap Core Growth C
WXCRX16.14N/A
N/A
William Blair Emerg Mkts ex China Gr R6

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+0.41%
RAIN - LSTA
29%
Poorly correlated
+13.68%
LGVN - LSTA
27%
Poorly correlated
+3.52%
CRIS - LSTA
27%
Poorly correlated
+2.60%
TPST - LSTA
26%
Poorly correlated
+3.85%
ASND - LSTA
26%
Poorly correlated
-2.51%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+6.07%
XNCR - RCUS
54%
Loosely correlated
+2.03%
IDYA - RCUS
49%
Loosely correlated
+4.27%
IMNM - RCUS
48%
Loosely correlated
+3.70%
APGE - RCUS
48%
Loosely correlated
+3.25%
NUVB - RCUS
47%
Loosely correlated
+8.50%
More